
Please try another search
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Name | Age | Since | Title |
---|---|---|---|
Jeffry R. Keyes | 52 | 2018 | Independent Director |
John Michael Climaco | 56 | 2017 | CEO, President & Director |
Faith L. Charles | - | 2022 | Independent Chairman of Board |
Amy Mahery | 48 | 2024 | Independent Director |
Sigmund Hsu | - | - | Scientific Advisory Board Member |
Jerzy Gumulka | 76 | 2017 | Independent Director |
Bettina M. Cockroft | 58 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review